Trimonthly vs. monthly use of bone-targeted agents in patients with bone metastases and multiple myeloma
Record ID 32018001646
English
Details
Project Status:
Ongoing
URL for project:
https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/bonetargetingagents.html
Anticipated Publish Date:
2022
URL for additional information:
https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-programm.html
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
Switzerland
MeSH Terms
- Denosumab
- Neoplasm Metastasis
- Bone Density Conservation Agents
- Bone Neoplasms
- Zoledronic Acid
- Multiple Myeloma
- Ibandronic Acid
- Diphosphonates
Keywords
- bone-targeted agents
- bone metastases
- multiple myeloma
- zoledronate
- ibandronate
- denosumab
- cancer-induced pain
- hypercalcaemia
- fracture risk
- PROMs
- efficacy
- effectiveness
- safety
- costs
- economics
- cost-effectiveness
- budget impact
- legal
- social
- ethical
- organisational
Contact
Organisation Name:
Swiss Federal Office of Public Health (FOPH)
Contact Address:
Federal Office of Public Health, Schwarzenburgstrasse 157, CH-3003 Berne, Switzerland
Contact Name:
Stephanie Vollenweider
Contact Email:
hta@bag.admin.ch
Copyright:
Swiss Federal Office of Public Health
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.